Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @alsassociation
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @alsassociation
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi
-
Congratulations to Bernard Muller from Project MinE
@_Makeityours - recipient of the#ALS Patient Impact Award at#alssymp! So inspiring and well deserved!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
In the last year, more than 48,000 people viewed, downloaded, or ordered our new educational materials, including the Living with ALS and Families and ALS resource guides and medical information packets. http://bit.ly/2ktp7iI
#ALS#MND#alssympHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Whether it’s
#StemCells, gene therapy, or RNA, we’ve made major progress in innovative#ALS research in 2017. Find out more about the progress we made this year: http://bit.ly/2jYkyZO#MND#alssymppic.twitter.com/79ygyVkirW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
A former Milton Safenowitz postdoctoral fellow Marka van Blitterswijk
@MayoClinic is looking at people w C9ORF72 mutation to identify new#ALS disease pathways which translate into new therapeutic targets. Great work!#alssympHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Advocates built support for the ALS Disability Insurance Access Act in Congress this year, a key priority to improve access to needed services for people living with
#ALS.#MND#alssymppic.twitter.com/XrLMKasQEs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Great to hear the fast progress out of
@AnswerALS and its new partnership with Project MinE@Makeityours. Collaborations are key to finding a cure for#ALS!#alssymp Learn more:http://bit.ly/2rejCmxHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
We wrapped up the ALS IMPACT Survey in 2017! With the help of the almost 1,000 responses from our
#ALS community, we’ll be better able to develop strategies to empower both caregivers and people living with ALS!#MND#alssymppic.twitter.com/EHKyyQMFeN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
The ALS Association and our advocates joined with other leading organizations to protect the rights of people living with
#ALS who are on Medicaid, ensuring access to care.#MND#alssymppic.twitter.com/sYNc1U1TEo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Throughout 2017, we collaborated with 130+ clinical partners, incorporating American Academy of Neurology best practices. http://bit.ly/2ktp7iI
#ALS#MND#alssympHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
IMPACT ALS survey results shows that burden of
#ALS is high – another step closer to establishing the burdens of daily life & identifying unmet medical needs of our community. We are excited to continue these critical studies! More results coming soon.#alssymp@Cytokineticspic.twitter.com/M2YLhjrvI9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Part of ALS PREFER – IMPACT ALS survey - was sent to people w
#ALS & caregivers to gather data about disease burden, functional outcomes and treatment views. Thrilled to see a great response – 1,534 participants. Thank you to all that took part!#alssymp@Cytokineticspic.twitter.com/14eHZGoGdC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
It is important for ppl w
#ALS to give input & integrate into drug development process. Together w@Cytokinetics & collaborators, we are developing ALS PREFER – a research driven platform building robust ALS patient preference studies. Thank u Lucie for presenting today!#alssymppic.twitter.com/74yjDV0iIa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Dr. Bjorn Oskarsson
@MayoClinic FL, Director of one of our Certified#ALS Clinics, is presenting an analysis of studies treating muscle cramps for those living with#ALS. So helpful to be as informed as possible.#alssymppic.twitter.com/IQR9ZQ1YEu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
After being newly diagnosed w
#ALS, many people wonder if they can still exercise. A brand new study by funded Dr. Maragakis@HopkinsMedicine is showing that you still can exercise safely and tolerably!#alssymp. Check out our blog for more: http://bit.ly/2ATYxX8 pic.twitter.com/urC6TmPXbD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
In 2004 we invested $1.5 million in
#antisense therapy research. Fast forward to 2017, and we’ve already seen one@US_FDA approved drug & one more#ALS treatment drugs in clinical trials.#ALSresearch#MND#alssymppic.twitter.com/5ofzBXwn8S
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Close collaborator, Dr. Kevin Horton
@CDCgov & National#ALS Registry presents findings about how close ppl living with ALS are to clinics, 1 key to ensuring that all members of the ALS community have access to the care & support they need. Thank u for your hard work!#alssymppic.twitter.com/nAJfelCboY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi
-
On stage now at
#alssymp Sheila Essey-award winner Adriano Chio presents studies#ALS to explore number of events that are necessary to cause neurodegeneration & how genetic mutations impact this number.pic.twitter.com/dqtYfskqCH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi -
Dr. Michael Benatar
@univmiami, one of our funded researchers, discusses insight into the longitudinal#ALS biomarker study of blood and CSF - called NfL- shows possible first biochemical biomarker of pre-symptomatic disease. Very exciting!#alssymppic.twitter.com/27JlTi8p2Y
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. Poništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.